TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2023

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.

Ulf Müller-Ladner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.